Suven Life Sciences rose 4.5% in the opening bell session, going up to Rs.266.80. Stock has gained after 2 days of consecutive fall.
The company announced the grant of one product patent from Israel, one product patent from Japan , one product patent from New Zealand and one product patent from Sri Lanka corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases.
The company said that patents are valid through 2036 and 2029 respectively.
The company currently has nine internally-discovered therapeutic drug candidates, presently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.